GR 159897

a selective non-peptide antagonist at tachykinin NK2 receptors; structure given in first source

Also Known As:

1-(2-(5-fluoro-1H-indol-3-yl)ethyl)-4-methoxy-4-((phenylsulfinyl)methyl)piperidine; GR-159897; GR159897

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Breast Neoplasms (Breast Cancer) 08/01/2020 - "The effects of highly potent and selective non-peptide mouse NK1R and NK2R antagonists RP 67580 and GR 159897, respectively, on metastatic breast carcinoma were evaluated. " 12/01/2018 - "The effects of highly potent and selective non-peptide mouse NK1R and NK2R antagonists RP 67,580 and GR 159897, respectively, as well as SP and SP methyl ester, on both metastatic (4THM, 4TBM, 4TLM, 4T1) and non-metastatic (67NR) breast cancer cells were determined. "
2.	Hypotension (Low Blood Pressure) 01/01/2018 - "Intravenous (IV) administration of NKA, LMN-NKA ([Lys5,MeLeu9,Nle10]-NKA(4-10)), and [β-Ala8]-NKA(4-10) caused a dose-related increase in colorectal pressure (up to 98 mmHg) that was blocked by pretreatment with the NK2R antagonist GR 159897 (1 mg/kg), and hypotension (decrease in mean arterial pressure of ~40 mmHg) that was blocked by the NK1R antagonist CP-99,994 (1 mg/kg). "

1.	Peptides (Polypeptides)
2.	Esters
3.	3- (2- methoxybenzylamino)- 2- phenylpiperidine
4.	7,7- diphenyl- 2- (1- imino- 2- (2- methoxyphenyl)ethyl)perhydroisoindol- 4- one